De Novo Design of Protein-Binding Peptides by Quantum Computing
Lars Meuser, Alexandros Patsilinakos, Pietro Faccioli
TL;DR
This work advances de novo peptide design by integrating a physics-based, multi-scale framework with quantum annealing to explore the combined chemical and conformational space without relying on training data. A coarse-grained lattice model and Miyazawa-Jernigan–type energetics are encoded into a QUBO and solved on a D-Wave hybrid quantum-classical solver, followed by all-atom docking to refine poses. Validation via structure- and sequence-based analyses shows designed peptides reasonably recapitulate native contacts and correlates with experimental binders, while quantum optimization provides a diverse set of low-energy, high-affinity candidates comparable to state-of-the-art classical solvers. The results demonstrate that current quantum technologies can augment physics-based drug design, with potential for scaling to more complex targets and to small-molecule design, receptor flexibility, and ADMET considerations.
Abstract
In silico de novo design can drastically cut the costs and time of drug development. In particular, a key advantage of bottom-up physics-based approaches is their independence from training datasets, unlike generative models. However, they require the simultaneous exploration of chemical and conformational space. In this study, we address this formidable challenge leveraging quantum annealers. Focusing on peptide de novo design, we introduce a multi-scale framework that integrates classical and quantum computing for atomically resolved predictions. We assess this scheme by designing binders for several protein targets. The D-Wave quantum annealer rapidly generates a chemically diverse set of binders with primary structures and binding poses that correlate well with experiments. These results demonstrate that, even in their current early stages, quantum technologies can already empower physics-based drug design.
